Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 7/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | S1PR1 | P21453 | 4/20 | 0.58 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9261769 | 0.89 | ALDH1A1 (0.66) | SIGMAR1ALDH1A1KMT2A | |
| SCHEMBL13917983 | 0.86 | S1PR1 (0.75) | SIGMAR1S1PR1S1PR3L3MBTL1S1PR5 | |
| Hydrochloric Acid SCHEMBL9501568 | 0.84 | S1PR1 (0.73) | SIGMAR1S1PR1S1PR3L3MBTL1S1PR5 | |
| SCHEMBL19438565 | 0.83 | SIGMAR1 (0.61) | SIGMAR1S1PR1S1PR3L3MBTL1S1PR5 | |
| SCHEMBL10766680 | 0.83 | SIGMAR1 (0.66) | SIGMAR1S1PR1S1PR3L3MBTL1S1PR5 | |
| SCHEMBL10468745 | 0.82 | HDAC3 (0.71) | SIGMAR1S1PR1S1PR3L3MBTL1S1PR5 | |
| SCHEMBL13917989 | 0.81 | L3MBTL1 (0.81) | SIGMAR1L3MBTL1 | |
| SCHEMBL110777 | 0.81 | ALDH1A1 (0.76) | ALDH1A1L3MBTL1 | |
| SCHEMBL4254894 | 0.81 | SIGMAR1 (1.00) | SIGMAR1 | |
| SCHEMBL30849612 | 0.81 | S1PR1 (0.71) | SIGMAR1S1PR1S1PR3S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9840731-B2 | Preservation of biological materials in non-aqueous fluid media | GENTEGRA, LLC (US) | 2017-12-12 | — | — | US | disclosed |
| US-20150267245-A1 | PRESERVATION OF BIOLOGICAL MATERIALS IN NON-AQUEOUS FLUID MEDIA | GENTEGRA, LLC (US) | 2015-09-24 | — | — | US | disclosed |
| WO-2014197090-A2 | PRESERVATION OF BIOLOGICAL MATERIALS IN NON-AQUEOUS FLUID MEDIA | GENTEGRA, LLC (US) | 2014-12-11 | — | — | WO | disclosed |
| WO-2014055936-A1 | PRESERVATION OF BIOLOGICAL MATERIALS IN NON-AQUEOUS FLUID MEDIA | INTEGENX INC. (US) | 2014-04-10 | — | — | WO | disclosed |
| US-7494989-B2 | Pyridine compounds useful as N-type calcium channel antagonists | AJINOMOTO CO., INC. (JP) | 2009-02-24 | — | — | US | disclosed |
| US-20080070903-A1 | NEW PYRIMIDINE DERIVATIVES AND NEW PYRIDINE DERIVATIVES | AJINOMOTO CO., INC (JP) | 2008-03-20 | — | — | US | disclosed |
| US-7288544-B2 | Pyrimidine compounds useful as N-type calcium channel antagonists | AJINOMOTO CO., INC. (JP) | 2007-10-30 | — | — | US | disclosed |
| US-20040009991-A1 | Pyrimidine derivatives and new pyridine derivatives | AJINOMOTO CO., INC. (JP) | 2004-01-15 | — | — | US | disclosed |
| EP-1318147-A1 | NOVEL PYRIMIDINE DERIVATIVE AND NOVEL PYRIDINE DERIVATIVE | Ajinomoto Co., Inc. (JP) | 2003-06-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070903-A1 | NEW PYRIMIDINE DERIVATIVES AND NEW PYRIDINE DERIVATIVES | P2RY10, CACNA1B, CACNA1E | SIGMAR1 983/4885ALDH1A1 2263/4885S1PR1 1312/4885 |
| US-20040009991-A1 | Pyrimidine derivatives and new pyridine derivatives | CACNA1I, CACNA1B, CACNA1E | SIGMAR1 1535/4885ALDH1A1 840/4885S1PR1 1297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.